VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 37 filers reported holding VERONA PHARMA PLC in Q4 2020. The put-call ratio across all filers is 1.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $102,000 | -15.7% | 18,560 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $121,000 | -22.4% | 18,560 | -0.7% | 0.01% | -27.3% |
| Q1 2021 | $156,000 | +20.0% | 18,690 | +0.7% | 0.01% | 0.0% |
| Q4 2020 | $130,000 | -4.4% | 18,560 | -14.7% | 0.01% | -21.4% |
| Q3 2020 | $136,000 | +33.3% | 21,760 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $102,000 | +13.3% | 21,760 | 0.0% | 0.01% | +7.7% |
| Q1 2020 | $90,000 | -23.7% | 21,760 | +6.4% | 0.01% | -7.1% |
| Q4 2019 | $118,000 | +25.5% | 20,460 | 0.0% | 0.01% | +7.7% |
| Q3 2019 | $94,000 | +6.8% | 20,460 | +18.1% | 0.01% | 0.0% |
| Q2 2019 | $88,000 | -22.1% | 17,330 | 0.0% | 0.01% | -31.6% |
| Q1 2019 | $113,000 | – | 17,330 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |